ACCESS TO MEDICINES
The fight for universal access to medicines has been one of our fundamental pillars in 2017.
We have opposed the patent of sofosbuvir, the expensive drug for Hepatitis C. We have actively participated in national, European and international political processes dealing with access to medicines as well as scientific policies such as Horizon 2020. We have continued working with different players to develop a new model of research, innovation, and development of drugs.
In addition, the No es Sano campaign, of which we are driving promoters, has continued adding to its ranks and carrying out key activities.